Feb. 17 at 12:44 PM
$NMTC NMTC just filed its 10-Q and the key takeaway is rising risk of survival.
Management issued a going-concern warning, cash has dropped to about
$3.6M, and they estimate runway only into late 2026 without new financing. They also disclosed that essentially all product revenue currently comes from a single customer, and the stock remains under Nasdaq’s
$1 compliance threshold.
Bottom line: the technology is real and products are FDA-cleared, but the immediate story is survival and dilution risk, not a near-term catalyst or repricing event. This continues to fall, reverse split, and fail on execution, even with Zimmer’s help.
